Extension for Roche's Herceptin drives Halozyme stock
This article was originally published in Scrip
San Diego-based Halozyme Therapeutics saw its stock shoot 24.8% higher on 28 June to close up $1.58 at $7.95 per share after the company announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of a line extension marketing application for a subcutaneous formulation of Roche's Herceptin (trastuzumab), which contains Halozyme's recombinant human hyaluronidase (rHuPH20).
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.